• Introduction & Clinical Interests:

    I am a clinician and clinical investigator with particular interest in lymphoma, including both B-cell and T-cell lymphomas. My priority is to deliver the best possible care to patients and increase access to clinical trials and state of the art therapies.


    In my research pursuits, I hope to help develop novel immune-based therapies for lymphoma that harness the immune system to achieve durable remissions with decreased toxicity.I am interested in immune-based therapies for lymphoma, including transplant, chimeric antigen receptor (CAR) T-cell therapy, and checkpoint blockade. I have a particular interest in immunotherapy and targeted therapy for cutaneous T-cell lymphomas.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Combined Kdm6a and Trp53 Deficiency Drives the Development of Squamous Cell Skin Cancer in MiceJournal of Investigative Dermatology2022
    2021 Enhanced Efficacy and Increased Long-Term Toxicity of CNS-Directed, AAV-Based Combination Therapy for Krabbe Disease.Molecular Therapy.  29:691-701. 2021
    2020 A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma.Biology of Blood and Marrow Transplantation.  26:2223-2228. 2020
    2020 Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.Current Hematologic Malignancy Reports.  15:9-19. 2020
    2019 Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation statusBlood Cancer Journal.  9. 2019
    2019 Choosing induction chemotherapy in therapy-related acute myeloid leukemia.Best Practice and Research: Clinical Haematology.  32:89-97. 2019
    2018 Primary Bone Marrow Diffuse Large B-cell Lymphoma Presenting as Transverse MyelitisAmerican Journal of the Medical Sciences.  356:561-566. 2018
    2017 Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia.Clinical Case Reports.  5:899-901. 2017
    2015 Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy. 2015
    2015 Prognostic significance of [18F]fluorodeoxyglucose-positron emission tomography in peripheral T-cell lymphoma treated with stem cell transplantation: a retrospective analysis. 2015
    2012 Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.Nature.  482:400-404. 2012
    2010 The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.PLoS One.  5:e15755. 2010
    2009 Monitoring autophagy in lysosomal storage disorders.Methods in Enzymology.  453:417-449. 2009
    2008 Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease.Human Molecular Genetics.  17:3897-3908. 2008


    Year Title Altmetric
    2020 Chronic Leukemias.  541-563. 2020

    Education And Training

  • The University of Alabama at Birmingham Internal Medicine, Residency
  • Washington University in St. Louis School of Medicine Hematology & Oncology, Postdoctoral Fellowship
  • Doctor of Medicine, Washington University/St. Louis 2014
  • Master of Science in Immunology, Washington University in St. Louis 2011
  • Bachelor of Science or Mathematics in Chemistry, Duke University 2007
  • Bachelor's Degree in Biology, Duke University 2007
  • Full Name

  • Lauren Shea